We used imatinib, a small molecule tyrosine kinase inhibitor that was originally developed to inhibit the BCR-ABL fusion protein in leukemia [27] but also inhibits c-Kit, PDGF receptors, and CSF1R and is being investigated as a possible chemotherapy for metastatic melanoma [28, 29]. This evidence concerns the gene BCR and leukemia.